A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
20 May, 2026
TROG trials in the spotlight at ESTRO26 international conference
LATEST NEWS: 20 MAY A number of TROG trials
18 May, 2026
FASTRACK II trial finds emerging radiotherapy technique effectively controls kidney cancer
LATEST NEWS: 18 MAY 2026 A new non-invasive form